Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 11,570,000 shares, a growth of 646.5% from the November 30th total of 1,550,000 shares. Based on an average daily volume of 25,630,000 shares, the short-interest ratio is presently 0.5 days.

Insider Activity

In other Conduit Pharmaceuticals news, major shareholder Ltd Nirland sold 1,016,823 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $0.12, for a total value of $122,018.76. Following the sale, the insider now directly owns 11,483,177 shares in the company, valued at approximately $1,377,981.24. The trade was a 8.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 3,658,000 shares of company stock valued at $386,136. Company insiders own 30.93% of the company’s stock.

Conduit Pharmaceuticals Stock Down 1.5 %

CDT stock traded down $0.00 on Thursday, hitting $0.06. 7,913,974 shares of the company’s stock traded hands, compared to its average volume of 10,052,146. The stock has a fifty day moving average of $0.09 and a 200-day moving average of $0.32. Conduit Pharmaceuticals has a 1-year low of $0.05 and a 1-year high of $5.44.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.